Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:27:05.886Z.
Calculation as of: 2026-10-06T16:27:05.886Z.
Quote observation: 2026-10-06T15:54:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dac276dab9b72f767ef95dff0a018bdb1655164ea652fec6d95688d7a2c4747
PE RATIO
N/A
Vyome Holdings, Inc.
Market Cap
$13.72M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Vyome Holdings, Inc. (HIND) | $13.72M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.77M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.83M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.91M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.47M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.38M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.94M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.95M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.96
Forward EPS (Est.)
$-0.65
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
